Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp (DE:EXK)
:EXK
EXK Stock Chart & Stats
€85.78
-€1.13(-2.05%)
At close: 4:00 PM EST
€85.78
-€1.13(-2.05%)
Day’s Range― - ―
52-Week Range€33.80 - €88.16
Previous CloseN/A
Volume60.00
Average Volume (3M)60.00
Market Cap
€16.44B
Enterprise Value€11.89B
Total Cash (Recent Filing)€1.00B
Total Debt (Recent Filing)€2.54B
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Feb 24, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding189,765,820
10 Day Avg. Volume14
30 Day Avg. Volume60
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)4.31
Price to Sales (P/S)3.75
P/FCF Ratio138.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€84.37Price Target Upside-1.65% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth And ProfitabilityAbbott's strategic interest in Exact Sciences is driven by its accelerating growth, profitability, and position in preventative, predictive, and personalized diagnostics.
Premium AcquisitionEXAS shareholders will receive $105.00 in cash per share, a premium of nearly 50% compared to EXAS's closing price before the potential deal surfaced.
Strategic AcquisitionThe acquisition by Abbott is seen as a 'watershed' moment in the diagnostics industry, which could enhance sector valuations and lead to more mergers and acquisitions.
Bears Say
Downgraded RatingsThe analyst downgraded the rating on Exact Sciences from Buy to Neutral following the announced deal.
High Valuation ConcernsThe $23 billion enterprise value price is considered high, which could deter other companies from placing a competing bid for Exact Sciences.
Limited UpsideThe analyst downgraded Exact Sciences to a HOLD rating due to the limited upside potential of less than 5% from the current share price to the $105 offer.
Exact Sciences News
EXK FAQ
What was Exact Sciences Corp’s price range in the past 12 months?
Exact Sciences Corp lowest stock price was €33.80 and its highest was €88.16 in the past 12 months.
What is Exact Sciences Corp’s market cap?
Exact Sciences Corp’s market cap is €16.44B.
When is Exact Sciences Corp’s upcoming earnings report date?
Exact Sciences Corp’s upcoming earnings report date is Feb 24, 2026 which is in 66 days.
How were Exact Sciences Corp’s earnings last quarter?
Exact Sciences Corp released its earnings results on Nov 03, 2025. The company reported -€0.085 earnings per share for the quarter, missing the consensus estimate of -€0.052 by -€0.033.
Is Exact Sciences Corp overvalued?
According to Wall Street analysts Exact Sciences Corp’s price is currently Overvalued.
Does Exact Sciences Corp pay dividends?
Exact Sciences Corp does not currently pay dividends.
What is Exact Sciences Corp’s EPS estimate?
Exact Sciences Corp’s EPS estimate is -0.07.
How many shares outstanding does Exact Sciences Corp have?
Exact Sciences Corp has 189,765,820 shares outstanding.
What happened to Exact Sciences Corp’s price movement after its last earnings report?
Exact Sciences Corp reported an EPS of -€0.085 in its last earnings report, missing expectations of -€0.052. Following the earnings report the stock price went up 5.456%.
Which hedge fund is a major shareholder of Exact Sciences Corp?
Currently, no hedge funds are holding shares in DE:EXK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€84.37 (-1.65% Downside)
€84.37 (-1.65% Downside)
Blogger Sentiment
Bullish
DE:EXK Sentiment 70%
Sector Average 68%
Sector Average 68%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.68%
12-Months-Change
Fundamentals
Return on Equity
-34.54%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Exact Sciences Corp
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXK Company Deck
EXK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.View all DE:EXK earnings summariesEXK Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXK Stock 12 Month Forecast
Average Price Target
€84.37
▼(-1.65% Downside)
Technical Analysis
Options Prices
Currently, No data available
---